Country Trust Bank Buys 4,153 Shares of IQVIA Holdings Inc. $IQV

Country Trust Bank boosted its stake in IQVIA Holdings Inc. (NYSE:IQV) by 2.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 197,534 shares of the medical research company’s stock after purchasing an additional 4,153 shares during the quarter. Country Trust Bank owned about 0.12% of IQVIA worth $44,526,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Brighton Jones LLC increased its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares during the last quarter. Empowered Funds LLC increased its holdings in IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares during the last quarter. Sivia Capital Partners LLC bought a new stake in IQVIA in the second quarter valued at approximately $514,000. EverSource Wealth Advisors LLC increased its stake in IQVIA by 63.6% in the second quarter. EverSource Wealth Advisors LLC now owns 2,907 shares of the medical research company’s stock valued at $458,000 after purchasing an additional 1,130 shares in the last quarter. Finally, Guggenheim Capital LLC increased its stake in IQVIA by 3.0% in the second quarter. Guggenheim Capital LLC now owns 26,697 shares of the medical research company’s stock valued at $4,207,000 after purchasing an additional 787 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Down 1.5%

Shares of IQV stock opened at $170.66 on Tuesday. The firm has a fifty day moving average of $178.70 and a 200-day moving average of $204.76. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.09. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $247.04. The company has a market capitalization of $28.96 billion, a price-to-earnings ratio of 21.71, a P/E/G ratio of 1.67 and a beta of 1.39.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. During the same quarter in the prior year, the firm earned $3.12 earnings per share. The firm’s revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

IQV has been the subject of several recent analyst reports. BMO Capital Markets set a $250.00 target price on shares of IQVIA in a research note on Friday, February 6th. UBS Group lowered their target price on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a research note on Friday, February 6th. JPMorgan Chase & Co. lowered their target price on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a research note on Friday, February 6th. Morgan Stanley set a $240.00 price target on IQVIA in a report on Wednesday, February 11th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of IQVIA in a report on Thursday, January 22nd. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $229.13.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.